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Abstract
Greater body mass index (BMI) has been associated with increased risk of psoriasis in case–control and cross-sectional
studies, however, the evidence from prospective studies has been limited. We conducted a systematic review and dose–
response meta-analysis of different adiposity measures and the risk of psoriasis to provide a more robust summary of the
evidence based on data from prospective studies. PubMed and Embase databases were searched for relevant studies up to
August 8th 2017. Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated using a random effects
model. The summary relative risk (RR) for a 5 unit increment in BMI was 1.19 (95% CI 1.10–1.28, I2 = 83%, n = 7). The
association appeared to be stronger at higher compared to lower levels of BMI, pnonlinearity\ 0.0001, and the lowest risk
was observed at a BMI around 20. The summary RR was 1.24 (95% CI 1.17–1.31, I2 = 0%, pheterogeneity = 0.72, n = 3)
per 10 cm increase in waist circumference, 1.37 (95% CI 1.23–1.53, I2 = 0%, pheterogeneity = 0.93, n = 3) per 0.1 unit
increase in waist-to-hip ratio, and 1.11 (95% CI 1.07–1.16, I2 = 47%, pheterogeneity = 0.15, n = 3) per 5 kg of weight gain.
Adiposity as measured by BMI, waist circumference, waist-to-hip ratio, and weight gain is associated with increased risk of
psoriasis.
Keywords Body mass index  Waist circumference  Waist-to-hip ratio  Weight gain  Psoriasis  Systematic review 
Meta-analysis
Introduction
Psoriasis is a chronic immune-mediated inflammatory skin
disease which is characterized by patches of abnormal skin,
which typically are red, itchy and scaly [1]. The condition
affects approximately 2% of the general population, how-
ever, the prevalence has doubled over the recent decades in
some countries, reaching a lifetime prevalence of 5.8–11%
in Scandinavia [2, 3]. A diagnosis of psoriasis has been
associated with increased risk of coronary heart disease
[4, 5], atrial fibrillation [6], stroke [5–7], thromboembolism
[7], certain cancers [8], and possibly other conditions
[9–13]. Although several risk factors for psoriasis have
been suggested or established including age [14], family
history of psoriasis [15, 16], skin infections and skin dis-
orders [17], gallstones [18], smoking [19], alcohol con-
sumption [20], and physical inactivity [21, 22], much
remains to be learned.
Adiposity is associated with low-grade inflammation
through overproduction of inflammatory cytokines.
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s10654-018-0366-z) contains supplementary
material, which is available to authorized users.
& Dagfinn Aune
d.aune@imperial.ac.uk
1 Department of Epidemiology and Biostatistics, School of
Public Health, Imperial College London, St. Mary’s Campus,
Norfolk Place, Paddington, London W2 1PG, UK
2 Department of Nutrition, Bjørknes University College, Oslo,
Norway
3 Department of Endocrinology, Morbid Obesity and
Preventive Medicine, Oslo University Hospital, Oslo,
Norway
4 Department of Public Health and Nursing, Faculty of
Medicine, Norwegian University of Science and Technology,
Trondheim, Norway
5 Department of Dermatology, St. Olavs Hospital, Trondheim
University Hospital, Trondheim, Norway
6 German Diabetes Center (DDZ), Institute for Biometrics and
Epidemiology, Heinrich Heine University Du¨sseldorf,
Du¨sseldorf, Germany
123
European Journal of Epidemiology
https://doi.org/10.1007/s10654-018-0366-z(0123456789().,-volV)(0123456789().,- volV)
Activated macrophages in adipose tissue stimulate adipo-
cytes to secrete TNF-a, IL-1, IL-6, and IL-8, which may
contribute to the development of psoriasis [23, 24]. In
addition, higher levels of leptin, an adipokine related to
obesity, has also been associated with increased risk of
psoriasis [25–27]. A large number of cross-sectional and
case–control studies have reported a positive association
between adiposity and the risk of psoriasis [28–42]. A
meta-analysis from 2012 also suggested a positive associ-
ation between obesity (BMI of C 30 kg/m2) and psoriasis
[43], however, it was largely based on cross-sectional and
case–control studies, study designs which can be difficult
to rely on for causal inferences because (1) the temporality
of the association between the exposure and the disease is
not clear in cross-sectional studies, and (2) because case–
control studies may be hampered by recall and selection
biases. However, recently several prospective studies have
also reported on the association between body mass index
(BMI, kg/m2), abdominal fatness (waist circumference or
waist-to-hip ratio) or weight changes and the risk of pso-
riasis [17, 44–49]. A large study from the UK found a 33%
increase in the risk of psoriasis among obese participants
compared to normal weight (BMI of 18.5 to \ 25.0 kg/
m2) participants [17], while in the Nurses’ Health Study I
and II there was roughly a doubling in the relative risk
among those with grade 2 obesity (BMI of C 35 kg/m2)
compared to those with normal weight [44, 45]. Further-
more there was a doubling in the risk among obese par-
ticipants compared to normal weight participants in the
Danish National Birth Cohort [46]. In contrast, a large
Korean study only found a weak and non-statistically sig-
nificant association [48] and a Norwegian study did not
find a significant association with overweight or obesity
[47], while a second much larger Norwegian study found
an almost twofold increase in risk of psoriasis among obese
persons [49]. The lower BMI in the Korean population
compared to the European and American populations may
have contributed to the weaker association in that study.
With regard to overweight, the results have been less
consistent with three studies reporting statistically signifi-
cant positive associations [44, 45, 49], while other studies
found no clear association [17, 46, 47, 48]. Abdominal
fatness (waist circumference and waist-to-hip ratio) is a
better predictor of visceral fat than BMI [50], and may be
more strongly associated with insulin resistance than BMI
[51], however, it is unclear whether waist circumference or
waist-to-hip ratio is more strongly associated with psoriasis
than BMI. The few studies that investigated the association
between waist circumference, waist-to-hip ratio and weight
gain were consistent in reporting an increased risk with
increasing adiposity [44, 45, 49]. Given the limited number
of prospective studies and lack of data on abdominal fat-
ness in previous meta-analyses on adiposity and psoriasis
we therefore conducted a systematic review and dose–re-
sponse meta-analysis of prospective studies to clarify the
strength and shape of the dose–response relationship
between different measures of adiposity and the risk of
psoriasis.
Methods
Search strategy
We searched the PubMed and the Embase databases up to
August 8th 2017. The search terms used are found in the
Supplementary Text. We followed the PRISMA criteria for
the reporting of meta-analyses of observational studies
[52]. In addition, the reference lists of all the studies that
were included in the analysis and the reference list of a
published meta-analysis were searched for additional
studies [43]. DA and SS conducted the screening of the
literature search.
Study selection
Prospective or retrospective cohort studies, case-cohort
studies, or nested case–control studies of the association
between measures of body fatness and risk of psoriasis
were included. Relative risk (RR) estimates (hazard ratio,
risk ratio, odds ratio) had to be available with the 95%
confidence intervals (CIs) in the publication and for the
dose–response analysis, a quantitative measure of the
exposure and the total number of cases and person-years
had to be available in the publication. If there were several
publications from the same study we used the study with
the largest number of cases, or the study which provided
sufficient detail of data to be included in dose–response
analyses. A list of the excluded studies and exclusion
reasons is found in Supplementary Table 1.
Data extraction
We extracted from each study: The first author’s last name,
publication year, country where the study was conducted,
the name of the cohort, follow-up period, sample size, sex,
age, number of cases, assessment method of anthropo-
metric factors (measured vs. self-reported), type of
anthropometric measure, RRs and 95% CIs, and variables
adjusted for in the analysis. Data were extracted by DA and
checked for accuracy by SS.
Statistical analysis
Summary RRs and 95% CIs for a 5 unit increment in BMI,
5 kg increase in weight gain, 10 cm increment in waist
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circumference, and for a 0.1 unit increment in waist-to-hip
ratio (consistent with our previous analyses [53, 54]) were
estimated using a random effects model [55]. The average
of the natural logarithm of the RRs was estimated and the
RR from each study was weighted using random effects
weights [55]. A two-tailed p\ 0.05 was considered sta-
tistically significant.
The method described by Greenland and Longnecker
[56] was used for the dose–response analysis and study-
specific slopes (linear trends) and 95% CIs were computed
from the natural logs of the RRs and CIs across categories
of adiposity measures. The method requires that the dis-
tribution of cases and person-years or non-cases and the
RRs with the variance estimates for at least three quanti-
tative exposure categories are known. We estimated the
distribution of cases or person-years in studies that did not
report these, but reported the total number of cases and
person-years [53]. The mean level of BMI, waist circum-
ference, waist-to-hip ratio, and weight gain in each cate-
gory was assigned to the corresponding relative risk for
each study and for studies that reported these measures by
ranges, we estimated the midpoint in each category as the
average of the lower and upper bounds. For studies which
did not use the lowest category as the reference category
we converted the risk estimates so that the lowest category
became the reference category using the method by Ham-
ling [57]. A potential nonlinear dose–response relationship
between BMI, waist circumference, waist-to-hip ratio,
weight gain and psoriasis was examined by using fractional
polynomial models [58]. We determined the best fitting
second order fractional polynomial regression model,
defined as the one with the lowest deviance. A likelihood
ratio test was used to assess the difference between the
nonlinear and linear models to test for nonlinearity [58].
Study quality was assessed using the Newcastle–Ottawa
scale which rates studies according to selection, compara-
bility and outcome assessment with a score range from 0 to
9 [59].
Subgroup and meta-regression analyses were conducted
to investigate potential sources of heterogeneity including
study characteristics such as sex, duration of follow-up,
geographic location, number of cases, study quality and
adjustment for confounding factors. Heterogeneity between
studies was quantitatively assessed by the Q test and I2
[60]. Small study effects, such as publication bias, were
assessed by inspecting the funnel plots for asymmetry and
with Egger’s test [61] and Begg’s test [62], with the results
considered to indicate small study effects when p\ 0.10.
Sensitivity analyses excluding one study at a time were
conducted to clarify whether the results were simply due to
one large study or a study with an extreme result.
Results
We identified 7 prospective studies (7 publications)
[17, 44–49] that were included in the analyses of adiposity
and psoriasis risk (Table 1, Fig. 1). Characteristics of the
included studies are provided in Table 1. Four studies were
from Europe, two studies were from the US, and one study
was from Asia (Table 1).
Body mass index
Seven prospective studies [17, 44–49] were included in the
analysis of BMI and psoriasis risk including 17,636 cases
and 695 471 participants. The summary relative risk (RR)
for a 5 unit increment was 1.19 (95% CI 1.10–1.28,
I2 = 83.1%, pheterogeneity\ 0.0001) (Fig. 2a). There was no
evidence of publication bias with Egger’s test, p = 0.12, or
Begg’s test, p = 0.37 (Supplementary Fig. 1). In sensitiv-
ity analyses, the summary RR ranged from 1.16 (95% CI
1.08–1.25) when excluding the Nurses’ Health Study II
[44] to 1.22 (95% CI 1.14–1.30) when excluding the Korea
National Health Insurance Corporation study [48]. The
summary RR was 1.25 (95% CI 1.19–1.31, I2 = 1%,
n = 5) for women and 1.34 (95% CI 1.11–1.62, I2 = 35%,
n = 2) for men (Supplementary Table 2). There was evi-
dence of a nonlinear association between BMI and psori-
asis, pnonlinearity\ 0.0001, and there was a steeper increase
in risk at higher compared to lower levels of BMI, how-
ever, some evidence of increased risk was observed even
within the normal BMI range and the lowest risk was
observed with a BMI between 16.75 and 20 (Fig. 2b,
Supplementary Table 3).
Waist circumference
Three cohort studies [44, 45, 49] were included in the
analysis of waist circumference and psoriasis risk and
included 2068 cases among 179 411 participants. The
summary RR was 1.24 (95% CI 1.17–1.31, I2 = 0%,
pheterogeneity = 0.72) per 10 cm increase in waist circum-
ference (Fig. 3a). The summary RR was 1.22 (95% CI
1.15–1.30, I2 = 0%, n = 3) for women and 1.44 (95% CI
1.23–1.66, n = 1) for men. There was no evidence of a
nonlinear association between waist circumference and
psoriasis risk, pnonlinearity = 0.09 (Fig. 3b, Supplementary
Table 4).
Waist-to-hip ratio
Three cohort studies [44, 45, 49] were included in the
analysis of waist-to-hip ratio and psoriasis risk and inclu-
ded 2068 cases among 179 411 participants. The summary
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RR for a 0.1 unit increment in waist-to-hip ratio was 1.37
(95% CI 1.23–1.53, I2 = 0%, pheterogeneity = 0.93) per 0.1
unit increase in waist-to-hip ratio (Fig. 4a). The summary
RR was 1.32 (95% CI 1.17–1.49, I2 = 0%, n = 3) for
women and 1.31 (95% CI 1.14–1.51, n = 1) for men.
There was no evidence of a nonlinear association between
waist-to-hip ratio and psoriasis risk, pnonlinearity = 0.59
(Fig. 4b, Supplementary Table 5).
Weight changes
Three cohort studies [44, 45, 49] were included in the
analysis of weight changes (between age 18–20 and base-
line in the Nurses’ Health Studies I and II and between
baseline of HUNT 1 and baseline of HUNT 2) and psoriasis
risk and included 1968 cases among 171 074 participants.
The summary RR per 5 kg of weight gain was 1.11 (95%
CI 1.07–1.16, I2 = 46.8%, p = 0.15) (Fig. 5a). The sum-
mary RR was 1.10 (95% CI 1.07–1.14, I2 = 19%, n = 3)
for women and 1.27 (95% CI 1.08–1.48, n = 1) for men.
There was no evidence of a nonlinear association between
weight gain and psoriasis risk, pnonlinearity = 0.26 (Fig. 5b,
Supplementary Table 6). It was not possible to conduct
dose–response analyses of weight loss as all studies only
reported risk estimates for one category of weight loss,
however, the summary RR comparing weight loss with
stable weight was 0.89 (95% CI 0.69–1.13, I2 = 0%,
p = 0.50).
Subgroup analyses and study quality
In subgroup analyses, there was little evidence of hetero-
geneity between subgroups when stratified by sex, geo-
graphic location, number of cases, and adjustment for
confounding factors including age, smoking, alcohol, and
physical activity (pheterogeneity C 0.07 for all comparisons).
There was some evidence of heterogeneity when studies
were stratified by duration of follow-up, pheterogene-
ity = 0.03, with a stronger association among studies with a
longer duration of follow-up compared to a shorter dura-
tion of follow-up (C 10 vs.\ 10 years follow-up).
The mean (median) study quality scores were 7.3 (7.0)
out of 9 possible points for the seven studies included in the
dose–response analysis of BMI and psoriasis and five
studies had a score of 7 and two studies had a score of 8
points (Table 1).
Discussion
In this meta-analysis of prospective studies we found evi-
dence of an increased risk of psoriasis with higher BMI,
waist circumference, waist-to-hip ratio, and weight gain.
There was a 19, 24, 37, and 11% increase in the relative
risk of psoriasis for each 5 unit increment in BMI, 10 cm
increase in waist circumference, 0.1 unit increment in
waist-to-hip ratio and 5 kg of weight gain, respectively.
Although there was some evidence of nonlinearity of the
association between BMI and psoriasis, there was a clear
dose–response relationship, with the lowest risk observed
around a BMI of 20, and with a significant increase from a
BMI around 22.5–24, and risk increased exponentially with
increasing BMI. The associations between waist circum-
ference, waist-to-hip ratio, and weight gain and psoriasis
appeared to be linear. The findings are consistent with a
previous meta-analysis of cross-sectional and case–control
studies which found an increased risk with obesity [43],
however, to our knowledge this is the first meta-analysis of
only prospective studies to find an increased risk, and the
first meta-analysis to investigate the dose–response rela-
tionship between different measures of adiposity such as
abdominal adiposity and weight gain and psoriasis risk.
The previous meta-analysis reported a 66% increase in the
relative risk among obese subjects compared to normal
147 reporting on adiposity and psoriasis
4238 excluded based on title or 
abstract
140 articles excluded:
34 case-control studies
31 reviews
30 cross-sectional studies
13 comments, editorials, letters
5 case only studies
4 meta-analyses
4 patient populations
3 abstracts 
3 pediatric psoriasis
3 not relevant outcome
2 duplicates
2 no risk estimates
2 not relevant exposure
1 adolescent BMI
1 <3 categories of exposure
1 not relevant data
1 obesity diagnosis
7 publications (7 studies) included
4385 records identified in total:
1241 records identified in PubMed
3144 records identified in Embase
Fig. 1 Flow-chart of study selection
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weight subjects [43], while we found a 2–4 fold increase in
the risk of psoriasis among those at the high end of each
adiposity measure compared to those who were slim.
Several potential mechanisms may explain an associa-
tion between greater adiposity and increased psoriasis risk.
Adiposity is associated with chronic, low-grade inflam-
mation through overproduction of inflammatory cytokines.
Activated macrophages in adipose tissue stimulate adipo-
cytes to secrete inflammatory mediators such as TNF-a, IL-
1, IL-6, and IL-8 which may account for some of the
A
B
-
.8
1
1.5
2
3
5
R
R
15 20 25 30 35 40 45
BMI (units)
Best fitting fractional polynomial
95% confidence interval
-
 Relative Risk
 .5  .75 1 1.5  2  3
 Study
 Relative Risk
 (95% CI)
 Kim, 2017 1.05 ( 1.00, 1.10)
 Snekvik, 2017 1.30 ( 1.15, 1.47)
 Danielsen, 2016 1.10 ( 0.96, 1.26)
 Harpsøe, 2014 1.39 ( 1.10, 1.75)
 Kumar, 2013 1.21 ( 1.13, 1.30)
 Huerta, 2007 1.12 ( 1.05, 1.19)
 Setty, 2007 1.31 ( 1.21, 1.42)
 Overall 1.19 ( 1.10, 1.28)
Fig. 2 BMI and psoriasis
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pathologic changes observed in psoriasis patients [23, 24].
Studies in psoriasis patients have also found higher levels
of leptin [25–27], an adipokine that is positively correlated
to obesity. In addition a positive correlation between leptin
and the severity of psoriasis has been observed [25], while
lower levels of adiponectin [27, 63] have been found
among psoriasis patients. Leptin deficiency has been shown
to counteract psoriasis-like skin inflammation in a mouse
model, while leptin stimulation of human kerotinocytes has
shown to increase the proliferation and to induce secretion
of several pro-inflammatory proteins, two of the charac-
teristics of psoriasis [64]. Further support for an important
role of obesity in the etiology of psoriasis comes from the
observation that weight loss induced by diet and lifestyle
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changes or obesity surgery in obese psoriasis patients has
been found to lead to improvement or remission of the
condition over time [65–74]. A diet and exercise inter-
vention was also found to reduce concentrations of TNF-a,
IL-6, IL-8, C-reactive protein and monocyte chemoattrac-
tant protein 1 [75], which may contribute to improvement
of psoriasis. Although we did not find a significant asso-
ciation between weight loss and reduced psoriasis risk in
the current analysis, we were not able to conduct dose–
response analyses of weight loss and psoriasis risk because
the data were reported in only two categories. In addition,
the weight loss analysis was based on the total population
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(including those who were normal weight at baseline) so
more pronounced associations may have been observed if
those analyses had been restricted to those who were
overweight and/or obese at baseline.
Our meta-analysis has some limitations which may
affect the interpretation of the results. The main limitation
is the low number of prospective studies available report-
ing on waist circumference, waist-to-hip ratio, and weight
gain which limited our possibility to conduct subgroup
analyses and test for publication bias for these measures
and only one study reported on hip circumference.
Although it is possible that confounding may have affected
the results as overweight and obese persons usually are less
physically active and have unhealthier diets than normal
weight persons, it is unlikely that such confounding could
entirely explain the association because the risk associated
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with body fatness is much stronger than those observed for
both physical activity [21] and dietary factors [28]. In
addition, the results persisted in subgroup analyses by
adjustment for confounding factors and there was little
evidence of heterogeneity between these subgroups. Nev-
ertheless, the possibility that unidentified risk factors could
confound the associations cannot be entirely excluded.
There was some evidence of heterogeneity in the subgroup
analysis stratified by duration of follow-up, with a stronger
association among studies with a longer duration of follow-
up compared to a shorter follow-up. It is possible that this
to some degree also could reflect weight gain over time as
we found a positive association between weight gain and
psoriasis and because most of the studies only used the
baseline assessment for the analysis of BMI and psoriasis.
Two studies also found a stronger association between
updated BMI and psoriasis than with baseline BMI
[44, 45], which also might suggest that weight gain over
time could have led to the observed stronger association
among studies with longer follow-up.
Measurement errors in the assessment of height and
weight may have influenced our results. Although most of
the studies relied on self-reported height and weight, there
is generally a high correlation between self-reported and
measured height and weight and waist and hip circumfer-
ences [76, 77]. In addition, the results were similar when
studies were stratified by whether the anthropometric
measurements were measured or self-reported. Although
meta-analyses of published literature may be susceptible to
publication bias, we found no evidence of publication bias
with either Egger’s test or with Begg’s test or when visu-
ally inspecting the funnel plots, however, we may have had
limited power to detect such bias because of the moderate
number of studies, and we were not able to reliably test for
publication bias in the analyses of waist circumference,
waist-to-hip ratio and weight changes.
The assessment of psoriasis diagnoses was based on
self-report or validated self-report [44, 45, 47, 49] in some
studies and through linkages to medical records or reg-
istries in the remaining studies [17, 46, 48], however,
several of these studies validated the self-reported diag-
noses and found relatively high positive predictive values
of between 78% [3], 82% [17] and 92% [45]. While some
cases of psoriasis may go undiagnosed, any misclassifica-
tion of the outcome would tend to attenuate the observed
risk estimates because of the prospective nature of the
included studies.
Our meta-analysis also has several strengths. Because
we based our analysis on prospective studies ambiguity
with regard to the temporality of the associations is avoi-
ded, and in addition recall bias is not likely to explain our
findings, and there is also less possibility for selection bias.
In addition, our meta-analysis included large cohort studies
with relatively long follow-up and included 17,636 cases
and 695 471 participants in the BMI analysis, so we had
statistical power to detect even moderate associations. The
results were robust to the influence of single studies. The
current findings have important public health implications
as the prevalence of overweight and obesity has increased
globally over the last decades [78], and this could con-
tribute to an increased incidence of psoriasis as well as a
range of other chronic diseases over time. In a recent
Norwegian study approximately 25% of psoriasis cases
could be attributed to overweight and obesity suggesting an
important public health impact of excess weight on psori-
asis risk [49].
In summary, our meta-analysis confirms a positive
association between body fatness, waist circumference,
waist-to-hip ratio, and weight gain and psoriasis risk. Any
further studies should further assess the association
between abdominal obesity and weight changes and pso-
riasis risk. Our findings confirm the previous recommen-
dations to be as lean as possible within the normal BMI
range and suggest that avoiding excess weight gain in
adulthood may reduce the risk of psoriasis.
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